We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to use a multiphase optimisation strategy (MOST) to evaluate your digital health product.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
Data on the real-world efficacy of the COVID-19 vaccines.
How to use a quasi-experimental study to evaluate your digital health product.
Legislation title: Guidance on the application of Plant Protection Products (PPPs) for phytosanitary treatment of oak processionary moth (OPM).
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
How to use a patient-reported outcomes and experiences study to evaluate your digital health product.
Resources to help local commissioners achieve value for money by estimating the return on investment (ROI) and cost-effectiveness of public health programmes.
This page includes summaries of the winning bids for the Future RAN (FRANC) competition
Exeltis UK Limited has informed the MHRA regarding an inconsistency in the Patient Information Leaflet (PIL) packaged in cartons of the specified batches of Gepretix 100mg capsules.
Evaluations made by the Rapid Review Panel (RRP) on submitted products.
Introducing the new pre-application service for Nationally Significant Infrastructure Projects.
Product Safety Report for PTS Packers and Providers Pvt Surfaz-SN Triple Action Cream presenting a serious chemical risk.
Reducing the impact of future pandemics by making Diagnostics, Therapeutics and Vaccines available within 100 days. A report to the G7 by the pandemic preparedness partnership.
Refreshed checklist of efficiency measures for more cost effective prescribing.
Why to deploy regularly, deployment principles to follow, and how to do it.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).